Department of Metabolic Medicine, Graduate School of Medicine, Osaka University.
Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University.
J Atheroscler Thromb. 2022 Dec 1;29(12):1823-1834. doi: 10.5551/jat.63305. Epub 2022 Jul 20.
T-cadherin (T-cad) is a specific binding partner of adiponectin (APN), adipocyte-specific secretory protein. APN exhibits organ protection via the T-cad-dependent accumulation onto several tissues such as the aorta, heart, and muscle. Recently, for the first time, we showed that three forms (130, 100, and 30 kDa) of soluble T-cad existed in human serum and correlated with several clinical parameters in patients with type 2 diabetes. Nevertheless, the significance of soluble T-cad has not been elucidated in the acute stage of cardiovascular diseases. We herein examined soluble T-cad concentrations and investigated their clinical significance in patients with emergency hospital admission due to ST-segment elevation myocardial infarction (STEMI).
This observational study enrolled 47 patients with STEMI who were treated via primary percutaneous coronary intervention (PCI). Soluble T-cad and APN concentrations were measured by using an enzyme-linked immunosorbent assay. This study is registered with the University Hospital Medical Information Network (Number: UMIN 000014418).
Serum concentrations of soluble 130 and 100 kDa T-cad rapidly and significantly decreased after hospitalization and reached the bottom at 72 h after admission (p<0.001 and p<0.001, respectively). The patients with high soluble T-cad and low APN concentrations on admission showed a significantly higher area under the curve of serum creatine kinase-MB (p<0.01).
Serum soluble T-cad concentration changed dramatically in patients with STEMI, and the high T-cad and low APN concentrations on admission were associated with the myocardial infarction size. Further study is needed to investigate the usefulness of categorizing patients with STEMI by serum T-cad and APN for the prediction of severe prognoses.
T-钙黏蛋白(T-cad)是脂联素(APN)的特异性结合伴侣,APN 是一种脂肪细胞特异性分泌蛋白。APN 通过 T-cad 依赖性积累到主动脉、心脏和肌肉等几种组织中发挥器官保护作用。最近,我们首次表明,三种形式(130、100 和 30 kDa)的可溶性 T-cad 存在于人类血清中,并与 2 型糖尿病患者的几个临床参数相关。然而,可溶性 T-cad 在心血管疾病的急性期的意义尚未阐明。我们在此检查了可溶性 T-cad 浓度,并研究了它们在因 ST 段抬高型心肌梗死(STEMI)而紧急住院的患者中的临床意义。
本观察性研究纳入了 47 名接受经皮冠状动脉介入治疗(PCI)治疗的 STEMI 患者。通过酶联免疫吸附试验测量可溶性 T-cad 和 APN 浓度。该研究已在大学医院医疗信息网络(编号:UMIN 000014418)注册。
入院后可溶性 130 和 100 kDa T-cad 的血清浓度迅速且显著降低,并在入院后 72 小时达到最低点(分别为 p<0.001 和 p<0.001)。入院时可溶性 T-cad 高和 APN 浓度低的患者的血清肌酸激酶同工酶-MB 曲线下面积显著更高(p<0.01)。
STEMI 患者的血清可溶性 T-cad 浓度发生了显著变化,入院时高 T-cad 和低 APN 浓度与心肌梗死面积有关。需要进一步研究通过血清 T-cad 和 APN 对 STEMI 患者进行分类,以预测严重预后的有用性。